EPMC Pharma brings expertise on project management of regulatory approvals and sourcing for new formulations of off-patent medicines in the treatment of neonates.  Our goal is ultimately to bring new formulations or already proven and safe products to market that will increase the well-being of neonates.

We have been selected to take part in the European FP7 as an SME in two consortia addressing pain and infection in new born.  Our contribution is to focus on effective project management of the PIP, regulatory approval and sourcing.

Do you need more information?

Feel free to use our information request form.